Tolgabide

Tolgabide
Clinical data
ATC code
  • none
Legal status
Legal status
  • Investigational
Identifiers
  • 4-{[(E)-(3-Chloro-5-methyl-6-oxocyclohexa-2,4-dien-1-ylidene)(4-chlorophenyl)methyl]amino}butanamide
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC18H18Cl2N2O2
Molar mass365.25 g·mol−1
3D model (JSmol)
  • Cc1cc(cc(c1O)/C(=N/CCCC(=O)N)/c2ccc(cc2)Cl)Cl
  • InChI=1S/C18H18Cl2N2O2/c1-11-9-14(20)10-15(18(11)24)17(22-8-2-3-16(21)23)12-4-6-13(19)7-5-12/h4-7,9-10,24H,2-3,8H2,1H3,(H2,21,23)/b22-17+
  • Key:AOAFGVWKONLQRN-OQKWZONESA-N

Tolgabide (INN; development code SL-81.0142) is a drug which was patented by Synthélabo as an anticonvulsant but was never marketed.[1] It is an analogue of progabide and acts similarly to it as a prodrug of GABA, and therefore as an indirect agonist of the GABA receptors.[1][2]

  1. ^ a b Triggle DJ (1996). Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC. ISBN 0-412-46630-9.
  2. ^ "The use of common stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances" (PDF). 2002.[dead link]